TransMedics Announces Positive FDA Advisory Committee Vote for OCS Heart System
Panel votes 12 to 5 that benefits of OCS Heart System outweigh risks
News provided by
Share this article
Share this article
ANDOVER, Mass., April 6, 2021 /PRNewswire/ TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that after the review of TransMedics clinical evidence from the OCS Heart EXPAND trial, the associated Continued Access Protocol ( CAP ) results, as well as the OCS Heart PROCEED II trial, the Circulatory Systems Device Advisory Panel convened by the U.S. Food and Drug Administration ( FDA ) has issued a favorable vote in support of approval of the OCS Heart System to the FDA s Office of Health Technology 2 (Cardiovascular Devices). The panel voted 12 to 5, with 1 abstaining, that the benefits of the OCS Heart System outweigh i
TransMedics Announces Positive FDA Advisory Committee Vote for OCS Heart System
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
people who prayed and attended regular religious services had lower blood pressure
milforddailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from milforddailynews.com Daily Mail and Mail on Sunday newspapers.